203 related articles for article (PubMed ID: 30650517)
1. Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
Yang GJ; Ko CN; Zhong HJ; Leung CH; Ma DL
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30650517
[TBL] [Abstract][Full Text] [Related]
2. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
[TBL] [Abstract][Full Text] [Related]
3. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
[TBL] [Abstract][Full Text] [Related]
4. Identification of ryuvidine as a KDM5A inhibitor.
Mitsui E; Yoshida S; Shinoda Y; Matsumori Y; Tsujii H; Tsuchida M; Wada S; Hasegawa M; Ito A; Mino K; Onuki T; Yoshida M; Sasaki R; Mizukami T
Sci Rep; 2019 Jul; 9(1):9952. PubMed ID: 31289306
[TBL] [Abstract][Full Text] [Related]
5. Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Wu X; Fang Z; Yang B; Zhong L; Yang Q; Zhang C; Huang S; Xiang R; Suzuki T; Li LL; Yang SY
Bioorg Med Chem Lett; 2016 May; 26(9):2284-8. PubMed ID: 27020306
[TBL] [Abstract][Full Text] [Related]
6. Histone Lysine Demethylase KDM5 Inhibitor CPI-455 Induces Astrocytogenesis in Neural Stem Cells.
San TT; Kim J; Kim HJ
ACS Chem Neurosci; 2024 Apr; 15(7):1570-1580. PubMed ID: 38501572
[TBL] [Abstract][Full Text] [Related]
7. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
[TBL] [Abstract][Full Text] [Related]
8. The KDM5 inhibitor PBIT reduces proliferation of castration-resistant prostate cancer cells via cell cycle arrest and the induction of senescence.
Smith T; White T; Chen Z; Stewart LV
Exp Cell Res; 2024 Apr; 437(1):113991. PubMed ID: 38462208
[TBL] [Abstract][Full Text] [Related]
9. Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation.
Li S; He J; Liao X; He Y; Chen R; Chen J; Hu S; Sun J
Cell Biol Toxicol; 2023 Aug; 39(4):1641-1655. PubMed ID: 36112263
[TBL] [Abstract][Full Text] [Related]
10. Histone demethylase KDM5A regulates the functions of human periodontal ligament stem cells during periodontitis via the miR-495-3p/HOXC8 axis.
Niu F; Xu J; Yan Y
Regen Ther; 2022 Jun; 20():95-106. PubMed ID: 35509266
[TBL] [Abstract][Full Text] [Related]
11. Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer.
Duan Y; Du Y; Gu Z; Zheng X; Wang C
Front Cell Dev Biol; 2022; 10():887385. PubMed ID: 35493099
[No Abstract] [Full Text] [Related]
12. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
Li CY; Wang W; Leung CH; Yang GJ; Chen J
Mol Cancer; 2024 May; 23(1):109. PubMed ID: 38769556
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
14. Domain architecture and protein-protein interactions regulate KDM5A recruitment to the chromatin.
Kataria A; Tyagi S
Epigenetics; 2023 Dec; 18(1):2268813. PubMed ID: 37838974
[TBL] [Abstract][Full Text] [Related]
15. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.
Hou J; Wu J; Dombkowski A; Zhang K; Holowatyj A; Boerner JL; Yang ZQ
Am J Transl Res; 2012; 4(3):247-56. PubMed ID: 22937203
[TBL] [Abstract][Full Text] [Related]
16. A computer aided drug discovery based discovery of lead-like compounds against KDM5A for cancers using pharmacophore modeling and high-throughput virtual screening.
Tariq A; Rehman HM; Mateen RM; Ali M; Mutahir Z; Afzal MS; Sajjad M; Gul R; Saleem M
Proteins; 2022 Mar; 90(3):645-657. PubMed ID: 34642975
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of KDM5A in human cancer.
Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
[TBL] [Abstract][Full Text] [Related]
18. Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism.
Torres IO; Kuchenbecker KM; Nnadi CI; Fletterick RJ; Kelly MJ; Fujimori DG
Nat Commun; 2015 Feb; 6():6204. PubMed ID: 25686748
[TBL] [Abstract][Full Text] [Related]
19. Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Dai B; Huang H; Guan F; Zhu G; Xiao Z; Mao B; Su H; Hu Z
Biomed Pharmacother; 2018 Mar; 99():72-80. PubMed ID: 29324315
[TBL] [Abstract][Full Text] [Related]
20. The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis.
Oser MG; Sabet AH; Gao W; Chakraborty AA; Schinzel AC; Jennings RB; Fonseca R; Bonal DM; Booker MA; Flaifel A; Novak JS; Christensen CL; Zhang H; Herbert ZT; Tolstorukov MY; Buss EJ; Wong KK; Bronson RT; Nguyen QD; Signoretti S; Kaelin WG
Genes Dev; 2019 Dec; 33(23-24):1718-1738. PubMed ID: 31727771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
